Unaudited Financial results September 30, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Dr Lalchandani Labs reported revenue from operations of ₹205.10 lakhs for H1 FY26, down ~3.5% from ₹212.54 lakhs in H1 FY25. Total revenue rose to ₹234.40 lakhs mainly due to a sharp jump in other income (₹29.30 lakhs vs ₹0.38 lakhs). Profit after tax increased ~28% to ₹19.50 lakhs (vs ₹15.19 lakhs), translating to EPS of ₹0.45 (vs ₹0.35). The auditor issued a qualified review report flagging unpaid term loan installments (interest/penal interest not captured), non-provision of gratuity and leave encashment liabilities, and irregular deposit of statutory dues (ESI, EPF, TDS). Operating cash flow turned negative at ₹(13.12) lakhs versus positive ₹44.30 lakhs in FY25.
Mixed signals for shareholders — PAT growth looks healthy on the surface, but the revenue dip, negative operating cash flow, and qualified audit opinion with serious red flags (missed loan repayments, unprovided employee liabilities, irregular statutory dues) raise concerns about earnings quality and financial discipline. Investors should weigh the headline profit growth against the auditor's qualifications and weakening cash generation.